A citation-based method for searching scientific literature

Xiangyong Li, Chi Zhou, Ke Chen, Bingding Huang, Qi Liu, Hao Ye. Mol Oncol 2021
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The Eighth Edition Lung Cancer Stage Classification.
Frank C Detterbeck, Daniel J Boffa, Anthony W Kim, Lynn T Tanoue. Chest 2017
505
100

PyClone: statistical inference of clonal population structure in cancer.
Andrew Roth, Jaswinder Khattra, Damian Yap, Adrian Wan, Emma Laks, Justina Biele, Gavin Ha, Samuel Aparicio, Alexandre Bouchard-Côté, Sohrab P Shah. Nat Methods 2014
470
100

NetMHCpan-4.0: Improved Peptide-MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data.
Vanessa Jurtz, Sinu Paul, Massimo Andreatta, Paolo Marcatili, Bjoern Peters, Morten Nielsen. J Immunol 2017
499
100

Functional analysis reveals that RBM10 mutations contribute to lung adenocarcinoma pathogenesis by deregulating splicing.
Jiawei Zhao, Yue Sun, Yin Huang, Fan Song, Zengshu Huang, Yufang Bao, Ji Zuo, David Saffen, Zhen Shao, Wen Liu,[...]. Sci Rep 2017
34
100

Identification of cancer driver genes based on nucleotide context.
Felix Dietlein, Donate Weghorn, Amaro Taylor-Weiner, André Richters, Brendan Reardon, David Liu, Eric S Lander, Eliezer M Van Allen, Shamil R Sunyaev. Nat Genet 2020
38
100

Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients.
Xu-Chao Zhang, Jun Wang, Guo-Guang Shao, Qun Wang, Xiaotao Qu, Bo Wang, Christopher Moy, Yue Fan, Zayed Albertyn, Xiayu Huang,[...]. Nat Commun 2019
79
100

Inflation of tumor mutation burden by tumor-only sequencing in under-represented groups.
Yan W Asmann, Kaushal Parikh, P Leif Bergsagel, Haidong Dong, Alex A Adjei, Mitesh J Borad, Aaron S Mansfield. NPJ Precis Oncol 2021
1
100

Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response.
Peng Jiang, Shengqing Gu, Deng Pan, Jingxin Fu, Avinash Sahu, Xihao Hu, Ziyi Li, Nicole Traugh, Xia Bu, Bo Li,[...]. Nat Med 2018
518
100

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Hossein Borghaei, Luis Paz-Ares, Leora Horn, David R Spigel, Martin Steins, Neal E Ready, Laura Q Chow, Everett E Vokes, Enriqueta Felip, Esther Holgado,[...]. N Engl J Med 2015
100

Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma.
Xin Hu, Junya Fujimoto, Lisha Ying, Junya Fukuoka, Kazuto Ashizawa, Wenyong Sun, Alexandre Reuben, Chi-Wan Chow, Nicholas McGranahan, Runzhe Chen,[...]. Nat Commun 2019
31
100

Neoantigens in cancer immunotherapy.
Ton N Schumacher, Robert D Schreiber. Science 2015
100

EPHA mutation as a predictor of immunotherapeutic efficacy in lung adenocarcinoma.
Hua Bai, Jianchun Duan, Chengcheng Li, Wenzhuan Xie, Wenfeng Fang, Yu Xu, Guoqiang Wang, Rui Wan, Jing Sun, Jiachen Xu,[...]. J Immunother Cancer 2020
5
100

Genomic characterisation of pulmonary subsolid nodules: mutational landscape and radiological features.
Yanmeng Li, Xiao Li, Hao Li, Yifan Zhao, Ziyang Liu, Kunkun Sun, Xiang Zhu, Qingyi Qi, Bei An, Danhua Shen,[...]. Eur Respir J 2020
12
100

Clinical Challenges of Immune Checkpoint Inhibitors.
Maria de Miguel, Emiliano Calvo. Cancer Cell 2020
42
100

The immune system profoundly restricts intratumor genetic heterogeneity.
Idan Milo, Marie Bedora-Faure, Zacarias Garcia, Ronan Thibaut, Leïla Périé, Guy Shakhar, Ludovic Deriano, Philippe Bousso. Sci Immunol 2018
49
100

Lung cancer: current therapies and new targeted treatments.
Fred R Hirsch, Giorgio V Scagliotti, James L Mulshine, Regina Kwon, Walter J Curran, Yi-Long Wu, Luis Paz-Ares. Lancet 2017
100

Integrative Proteomic Characterization of Human Lung Adenocarcinoma.
Jun-Yu Xu, Chunchao Zhang, Xiang Wang, Linhui Zhai, Yiming Ma, Yousheng Mao, Kun Qian, Changqing Sun, Zhiwei Liu, Shangwen Jiang,[...]. Cell 2020
61
100

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe,[...]. N Engl J Med 2016
100

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
Scott J Antonia, Augusto Villegas, Davey Daniel, David Vicente, Shuji Murakami, Rina Hui, Takayasu Kurata, Alberto Chiappori, Ki H Lee, Maike de Wit,[...]. N Engl J Med 2018
100

Targeting neoantigens to augment antitumour immunity.
Mark Yarchoan, Burles A Johnson, Eric R Lutz, Daniel A Laheru, Elizabeth M Jaffee. Nat Rev Cancer 2017
376
100

TIMER2.0 for analysis of tumor-infiltrating immune cells.
Taiwen Li, Jingxin Fu, Zexian Zeng, David Cohen, Jing Li, Qianming Chen, Bo Li, X Shirley Liu. Nucleic Acids Res 2020
422
100

ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer.
Jiexia Zhang, Ningning Zhou, Anqi Lin, Peng Luo, Xin Chen, Huojin Deng, Shijun Kang, Linlang Guo, Weiliang Zhu, Jian Zhang. Cancer Immunol Immunother 2021
18
100

An integrated, functionally annotated gene map of the DXS8026-ELK1 interval on human Xp11.3-Xp11.23: potential hotspot for neurogenetic disorders.
Dawn L Thiselton, Jennifer McDowall, Oliver Brandau, Juliane Ramser, Fabiana d'Esposito, Shomi S Bhattacharya, Mark T Ross, Alison J Hardcastle, Alfons Meindl. Genomics 2002
84
100

RNA binding motif protein 10 suppresses lung cancer progression by controlling alternative splicing of eukaryotic translation initiation factor 4H.
Sirui Zhang, Yufang Bao, Xianfeng Shen, Yunjian Pan, Yue Sun, Man Xiao, Kexuan Chen, Huanhuan Wei, Ji Zuo, David Saffen,[...]. EBioMedicine 2020
3
100

Mutation-Derived Neoantigens for Cancer Immunotherapy.
John C Castle, Mohamed Uduman, Simarjot Pabla, Robert B Stein, Jennifer S Buell. Front Immunol 2019
33
100

Treatment after progression in the era of immunotherapy.
Salem Billan, Orit Kaidar-Person, Ziv Gil. Lancet Oncol 2020
29
100

Genomic Landscape and Immune Microenvironment Features of Preinvasive and Early Invasive Lung Adenocarcinoma.
Chao Zhang, Jianjun Zhang, Fang-Ping Xu, Yin-Guang Wang, Zhi Xie, Jian Su, Song Dong, Qiang Nie, Yang Shao, Qing Zhou,[...]. J Thorac Oncol 2019
26
100

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Roy S Herbst, Paul Baas, Dong-Wan Kim, Enriqueta Felip, José L Pérez-Gracia, Ji-Youn Han, Julian Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung-Ju Ahn,[...]. Lancet 2016
100

Genomic and immune profiling of pre-invasive lung adenocarcinoma.
Haiquan Chen, Jian Carrot-Zhang, Yue Zhao, Haichuan Hu, Samuel S Freeman, Su Yu, Gavin Ha, Alison M Taylor, Ashton C Berger, Lindsay Westlake,[...]. Nat Commun 2019
42
100

The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker.
Denis L Jardim, Aaron Goodman, Debora de Melo Gagliato, Razelle Kurzrock. Cancer Cell 2021
35
100

Cancer Statistics, 2021.
Rebecca L Siegel, Kimberly D Miller, Hannah E Fuchs, Ahmedin Jemal. CA Cancer J Clin 2021
100

SIFT missense predictions for genomes.
Robert Vaser, Swarnaseetha Adusumalli, Sim Ngak Leng, Mile Sikic, Pauline C Ng. Nat Protoc 2016
451
100

Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC.
Mark M Awad, Shirish M Gadgeel, Hossein Borghaei, Amita Patnaik, James Chih-Hsin Yang, Steven F Powell, Ryan D Gentzler, Renato G Martins, James P Stevenson, Mehmet Altan,[...]. J Thorac Oncol 2021
16
100

Tumor mutational burden is a determinant of immune-mediated survival in breast cancer.
Alexandra Thomas, Eric D Routh, Ashok Pullikuth, Guangxu Jin, Jing Su, Jeff W Chou, Katherine A Hoadley, Cristin Print, Nick Knowlton, Michael A Black,[...]. Oncoimmunology 2018
134
100


Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors.
Dan Sha, Zhaohui Jin, Jan Budczies, Klaus Kluck, Albrecht Stenzinger, Frank A Sinicrope. Cancer Discov 2020
37
100

RBM5, 6, and 10 differentially regulate NUMB alternative splicing to control cancer cell proliferation.
Elias G Bechara, Endre Sebestyén, Isabella Bernardis, Eduardo Eyras, Juan Valcárcel. Mol Cell 2013
182
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.